Table 3 |
|||
|
Characteristics of children receiving ART (n = 54) |
|||
|
At clinic enrollment |
At ART initiationa |
At study enrollment |
|
|
|
|||
|
Median age (yrs) (IQR) |
3.6 (1.5, 7.7) |
3.8 (2.0, 8.0) |
4.5 (2.7, 8.6) |
|
Median WAZ (IQR)b |
-2.7 (-3.5, -1.5) |
-2.5 (-3.9, -1.8) |
-2.4 (-3.2, -1.5) |
|
WAZ <-2 |
27 (61.4) |
28 (70.0) |
26 (60.5) |
|
WAZ ≥-2 |
17 (38.6) |
12 (30.0) |
17 (39.5) |
|
Median CD4+ T cell % (IQR) |
14.0 (9.2, 19.0) |
12.4 (9.2, 18.6) |
28.6 (23.5, 36.1) |
|
Median CD4+ T cell count (IQR) |
505 (281, 985) |
368 (219, 559) |
973 (466, 1522) |
|
Severe immunodeficiencyc |
16 (50) |
24 (63) |
2 (5) |
|
Median total lymphocyte count (IQR) |
3194 (1948, 5351) |
2747 (1634, 5351) |
3372 (1862, 5276) |
|
Median hemoglobin (IQR) |
10.6 (10.0, 11.7) |
10.8 (10.0, 12.0) |
11.9 (10.6, 12.3) |
|
Hemoglobin <8 gm/dL |
1 (2.0) |
0 (0) |
4 (8.9) |
|
Hemoglobin ≥8 gm/dL |
49 (98.0) |
36 (100.0) |
41 (91.1) |
|
WHO stage |
|||
|
1 |
2 (5.1) |
2 (7.1) |
6 (17.7) |
|
2 |
9 (23.1) |
1 (3.6) |
6 (17.7) |
|
3 |
22 (56.4) |
20 (71.4) |
20 (58.8) |
|
4 |
6 (15.4) |
5 (17.9) |
2 (5.9) |
|
ART regimen |
|||
|
AZT/3TC/EFV |
--- |
12 (26.1) |
11 (42.3) |
|
AZT/3TC/NVP |
--- |
11 (23.9) |
7 (26.9) |
|
d4T/3TC/EFV |
--- |
5 (10.8) |
2 (7.7) |
|
d4T/3TC/NVP |
--- |
18 (39.1) |
6 (23.1) |
|
|
|||
|
ART = antiretroviral therapy; IQR = interquartile range; WAZ = weight-for-age Z score; WHO = World Health Organization; AZT = zidovudine; 3TC = lamivudine; EFV = efavirenz; NVP = nevirapine; d4T = stavudine a7 children transferred to Macha and had already initiated ART bfor children <10 yrs old csevere immunodeficiency defined by age according to WHO guidelines |
|||
|
van Dijk et al. BMC Infectious Diseases 2009 9:169 doi:10.1186/1471-2334-9-169 |
|||
